Daily Archives: August 8, 2020

Première biopsie liquide à recevoir l’approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.

SINGAPOUR, 8 août 2020 /PRNewswire/ — La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides. Pour Guardant Health Asia, Middle East and Africa (AMEA), cette approbation de la FDA

Première biopsie liquide à recevoir l’approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.

SINGAPOUR, 8 août 2020 /PRNewswire/ — La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides. Pour Guardant Health Asia, Middle East and Africa (AMEA), cette approbation de la FDA […]

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

SINGAPORE, Aug. 8, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

SINGAPORE, Aug. 8, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is […]

Policy Weekly Vol.3 Issue 28, August 07 – 14, 2020: Assessing the MNJTF Mission

The Multinational Joint Task Force (MNJTF) was launched by the Lake Chad Basin states and Benin on October 7, 2014, in a bid to mitigate the growing regionalisation of the Boko Haram terrorism. The regional stabilisation strategy was an expansion of the solely Nigerian task force established on March 21, 1994, by the Abacha administration

Global Food Security Alert, July 31, 2020: COVID-19 pandemic drives global increase in humanitarian food assistance needs

A rise in urban food insecurity occurs alongside efforts to suppress the spread of the virus FEWS NET is monitoring the multiple impacts of the COVID-19 pandemic on acute food insecurity in the countries it covers. This Global Food Security Alert is a part of a monthly series that aims to provide an update of

UNICEF Cameroon Humanitarian Situation Report No. 6 – Mid-Year Report: January – June 2020

Highlights • Humanitarian delivery for children affected by the NWSW crisis was further constrained by increased violence and displacements of 60,000 people. Aid agencies faced escalating threats including attacks on staff. • In Far North region, children and communities continued to be instrumentalized and traumatized by Boko Haram attacks with an increase in killings, rape,